Orlaith Bogg, MSc

Clinical Scientist
Pyxis Oncology
Boston, Massachusetts, United States

Presentation(s):

• Paper 09 - FIRST-IN-CLASS NON-CELLULAR TARGETING ANTIBODY-DRUG CONJUGATE (ADC), MICVOTABART PELIDOTIN (MICVO), IN PATIENTS (PTS) WITH ADVANCED SARCOMA

  Thursday, November 13, 2025
  11:30 AM - 12:30 PM EST

  Disclosure information not submitted.